- Home
- PEGA vs MDGL Comparison
PEGA vs MDGL Comparison
Compare PEGA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | MDGL |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.6B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | PEGA | MDGL |
|---|---|---|
| Price | $54.48 | $582.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $66.08 | ★ $543.33 |
| AVG Volume (30 Days) | ★ 1.1M | 439.0K |
| Earning Date | 10-21-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 116.89 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $1,732,325,000.00 | $740,640,000.00 |
| Revenue This Year | $18.29 | $395.75 |
| Revenue Next Year | $6.66 | $65.73 |
| P/E Ratio | $37.17 | ★ N/A |
| Revenue Growth | 17.00 | ★ 864.21 |
| 52 Week Low | $29.84 | $265.00 |
| 52 Week High | $68.10 | $605.00 |
Technical Indicators
Market Signals| Indicator | PEGA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 67.10 |
| Support Level | $53.74 | $535.00 |
| Resistance Level | $55.00 | $605.00 |
| Average True Range (ATR) | 1.90 | 28.28 |
| MACD | -0.24 | 3.59 |
| Stochastic Oscillator | 36.01 | 76.47 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.